Post-Treatment Blood Test Offers New Hope for Personalized Cancer Therapy Decisions: Study Finds
Advertisement
A new Yale study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer years after their treatment.
This tool is a type of molecular residual disease (MRD) detector, which is used after patients have completed their primary treatment in order to monitor their cancer status. Researchers say it could inform clinical intervention, including whether to restart or intensify treatment.
The study findings, published in Nature Medicine were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with non-small cell lung cancer (NSCLC) with epidermal growth factor (EGFR)-activated mutations. The ADAURA trial findings showed a significant benefit in disease-free survival with osimertinib, compared to placebo, making it the recommended standard of treatment for patients up to three years after surgery.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.